CCL5 and graft versus host disease: In agreement with results described above, at day 10 after the transplant, there was no difference between the levels of TNF-α, IFN-γ, CCL2, CCL3 and CCL5 in the mice with experimental GVHD regardless of whether they received treatment with fullerol (data not shown).